Last updated: May 24, 2026
Depacon clinical trials update, market analysis and projection (valproate sodium for injection)
Depacon (divalproex sodium/valproate sodium product portfolio for injection in the US) has limited visibility for new Phase 3 entrants in the open literature. Market exposure is driven by hospital use of IV valproate/valproate salts for acute seizure control, conversion from oral therapy, and status epilepticus treatment pathways. Near-term growth expectations are tied to hospital formulary decisions, seizure volume trends, and competitive positioning against IV levetiracetam, lacosamide, and phenobarbital-based regimens, rather than brand-new clinical programs.
What clinical trials involve Depacon (valproate) and what are the latest updates?
Depacon is a branded valproate product used primarily in acute care settings. In public sources, recent trial activity tied specifically to “Depacon” (brand-labeled) is sparse relative to trials that enroll on active ingredient (valproate/valproic acid) or on other branded IV anti-seizure medicines.
What trial types typically map to IV valproate use in practice?
- Conversion studies from IV to oral valproate formulations
- Acute seizure and status epilepticus comparative-effectiveness studies using IV anti-seizure drugs
- Pharmacokinetic and formulation stability work for valproate salts in injectable form
- Safety surveillance in hospitalized populations
What do “latest updates” look like for an IV valproate brand?
In the absence of frequent brand-specific Phase 3 filings under the Depacon label, the most actionable “update” signals typically come from:
- FDA label changes for valproate/parenteral equivalents (safety, dosing, warnings)
- Hospital outcomes literature that compares IV valproate to competing agents
- Formulary lists and restricted-use policies that affect pull-through demand
No reliable, brand-specific Phase 3 “Depacon” updates can be stated from the open literature at this time using only verifiable public records in this context.
What is Depacon’s FDA regulatory status and Orange Book listing for US exclusivity?
Depacon is marketed in the US as an injection formulation of valproate (valproate sodium and/or related valproate salt presentation depending on labeling and package). Regulatory status for parenteral valproate products is generally mature, with exclusivity largely determined by the underlying NDA/ANDA and the specific listed patents in the FDA Orange Book for the injectable dosage form.
Key regulatory checkpoints that affect access
- Orange Book patent listings for the injectable NDA (for brand and generic entry risk)
- Hatch-Waxman regulatory exclusivities (if any remain) and patent tail
- Any Risk Evaluation and Mitigation Strategy (REMS) or label restrictions that shift demand between alternatives
A complete and accurate Orange Book status map for “Depacon” requires the exact NDA number and the injectable listing details. Those specific listing identifiers are not provided in the prompt context, so an evidence-backed patent/exclusivity statement cannot be produced without risking incorrect dates or listings.
What does the competitive landscape for IV valproate look like vs status epilepticus alternatives?
In acute seizure management, IV valproate is competing against multiple standard-of-care options where availability, speed of titration, dosing simplicity, and adverse event profile drive hospital selection.
Primary IV/comparator categories hospitals often use
- IV benzodiazepines (first-line immediate seizure termination, not direct substitutes but drive sequencing)
- IV levetiracetam
- IV lacosamide
- IV phenobarbital
- IV phenytoin (less favored in some settings due to infusion and interaction issues)
- IV midazolam (where available)
How does this affect Depacon market dynamics?
- If protocols shift toward levetiracetam or lacosamide first-line in status epilepticus pathways, IV valproate use may contract to specific subpopulations (e.g., patients already stabilized on valproate, those with specific seizure types, or where prior response supports continuation).
- If hospitals maintain valproate on formulary as a continuation option, pull-through demand is tied to conversion pathways and inpatient prescribing patterns.
How big is the Depacon market and what revenue exposure matters?
A Depacon-specific market size requires either:
- company-reported segment data for the product line, or
- reliable third-party estimates by brand and dosage form.
No unit sales or revenue figure is included in the prompt, and a precise forecast would risk fabrication. What can be stated as actionable structure for projection is the demand model:
Demand drivers for IV Depacon/valproate injectable
- Hospital admissions and emergency seizure burden
- Status epilepticus protocol adoption
- Formulary tier placement (preferred vs non-preferred)
- Conversion from oral valproate to IV in peri-critical care settings
- Generic penetration levels for the same active ingredient and strength (pricing pressure)
What to watch in formularies and procurement
- Tender-based pricing and contracting for IV anti-seizure medications
- Substitution policies that allow pharmacists to swap to approved generics or therapeutically equivalent valproate salts
- Stock availability that influences acute-caretreatment selection
When does Depacon face generic and biosimilar entry risk?
For small-molecule injectables like valproate, “biosimilar” risk does not apply. The relevant competitive risk is generic entry and potentially authorized generics, governed by:
- NDA patent expirations
- Orange Book-listed patents covering formulation, method of use, and/or manufacturing
Without the exact Orange Book listings for Depacon’s NDA and injectable strength, the timing cannot be stated with accuracy.
What is the patent estate strength for Depacon and how many patents cover it?
Patent strength analysis must be grounded in the actual Orange Book patent list, including:
- patent numbers
- assignees
- expiration dates
- patent type (composition, method of use, formulation, manufacturing)
No patent list or NDA number is provided. A numeric count and legal “strength” summary would be speculative.
What Paragraph IV challenges exist for Depacon and what is the litigation status?
Paragraph IV challenges require:
- identification of ANDA filers
- settlement or court docket outcomes
- FDA approval status post-litigation
No ANDA/Paragraph IV data is included in the prompt, so litigation status and settlement timelines cannot be produced accurately.
How does Depacon compare with other anti-seizure injection brands on adoption and pricing pressure?
Adoption comparison levers
- Label fit for acute seizure/status epilepticus settings
- Dosing workflow (loading and maintenance)
- Administration constraints (infusion rates, IV compatibility)
- Contraindications and safety monitoring requirements
Pricing pressure levers
- Generic availability for injectable valproate equivalents
- Contract pricing and group purchasing organization (GPO) rates
- Competitor contracting against protocol-driven purchasing
Given that IV valproate is a widely available small molecule, Depacon’s pricing is typically constrained by therapeutic alternatives and by generic competition in the active ingredient category. A brand-by-brand quantification requires market pricing data by NDC and competitor WAC or net price.
Key market projection framework for Depacon (how the forecast should be built)
A projection for an injectable anti-seizure medicine should be built from three layers:
- Procedure and acute admission volume proxy
- Emergency department seizure presentations
- Inpatient critical care and neurology admissions where IV rescue therapy is used
- Treatment share by protocol
- Share of status epilepticus pathways using IV valproate (or continuation-only usage)
- Share shift when hospitals standardize on levetiracetam/lacosamide
- Pricing and formulary access
- Net price changes from contracting
- Incremental displacement from formulary restrictions
- Generic substitution for equivalent valproate injectable dosage strengths
This framework is actionable even when brand-specific clinical trial updates are limited, because hospital purchasing behavior is the dominant near-term determinant of injectable anti-seizure revenues.
Tables: what to compile for Depacon market modeling (inputs you will need)
Table 1: Depacon demand model inputs (per quarter)
| Input |
Unit |
Source type |
Why it matters |
| Seizure/status epilepticus inpatient cases |
cases |
hospital/payer datasets |
volume proxy |
| IV anti-seizure regimen share |
% |
formulary adherence studies |
protocol-driven |
| Depacon share within IV valproate subset |
% |
pharmacy purchasing |
product pull-through |
| Net price after contracting |
$ |
pricing files |
margin and revenue |
| Generic share/penetration of IV valproate |
% |
claims/purchasing |
substitution risk |
Table 2: Competitive substitution map (qualitative)
| Comparator |
Likely displacement mechanism vs IV valproate |
| IV levetiracetam |
protocol standardization and easier titration |
| IV lacosamide |
availability and tolerability profile |
| IV phenobarbital |
older alternative when benzodiazepines fail |
| IV phenytoin |
less favored where infusion complexity is a barrier |
Key Takeaways
- Depacon’s near-term clinical “update” signal is likely to come more from acute-care protocol evidence and label/regulatory updates than from new brand-specific late-stage trials.
- Market dynamics for IV valproate are driven primarily by hospital formulary decisions and seizure pathway protocol adoption, with strong competitive pressure from IV levetiracetam and lacosamide.
- Generic small-molecule competition and contracting economics are the dominant determinants of revenue trajectory; biosimilar risk is not applicable.
- A credible Depacon revenue projection requires brand-specific NDC-level pricing, volume proxies from acute-care settings, and share-of-protocol within status epilepticus treatment pathways.
FAQs
1) What are Depacon’s main clinical use cases in acute seizure care?
IV valproate products are typically used for acute seizure control and inpatient continuation/transition scenarios within hospital seizure management pathways.
2) Is Depacon used in status epilepticus protocols, and how does that affect demand?
When hospitals include IV valproate in their status epilepticus pathway, demand correlates with inpatient seizure burden; displacement from protocol standardization can reduce pull-through.
3) What happens to Depacon demand when hospitals prefer levetiracetam or lacosamide first-line?
If protocols shift first-line rescue selection, IV valproate often loses share, retaining use mainly for continuation or specific clinical subgroups.
4) Are there biosimilar threats to Depacon?
No. Depacon is a small-molecule injectable; biosimilar risk is not relevant.
5) What are the highest-impact variables for a Depacon market forecast?
Protocol share in acute seizure management, inpatient admission volume proxies, net price under contracting, and generic substitution penetration in equivalent IV valproate presentations.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. U.S. National Library of Medicine.
- FDA Drug Safety Communications and product labeling for valproate-containing products. U.S. Food and Drug Administration.
